12:00 AM
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NurOwn: Phase IIa started

BrainStorm began a dose-escalation, Israeli Phase IIa trial to evaluate combined intramuscular and intrathecal administration of NurOwn in 12 patients. The company said the Israeli Ministry of Health approved the...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >